Öz
Sonuç:
Nesfatin-1, glikoz seviyelerinin negatif düzenleyicisi olarak glikoz homeostazında rol oynar. Bu çalışmada düşük vücut kitle indeksi ve Nefsatin-1 ekspresyonu yüksek olan hastaların daha iyi bir post-operative klinik seyir gösterebileceği düşünülmüştür.
Bulgular:
Galectin-3, Ghrelin and Leptin ekspresyonu istatistiksel olarak metabolik sendromu olan ve olmayan hastalarda, post-operatif komplikasyonlar, yoğun bakım yatış süresi, vücut kitle indeksi ile anlamlı bir fark bulunmamaktadır (p>0,05). Bununla birlikte Nefsatin-1 ekspresyonu ile post-operatif komplikasyonlar, yoğun bakım yatış süresi ve metabolik sendrom riski ile anlamlı bir fark bulunmaktadır (sırasıyla, p=0,026, p=0,030, p=0,047).
Yöntem:
Çalışmaya CABG cerrahisi uygulanan ve sinüs ritminde olan 50 hasta dahil edilmiştir. Hastalar metabolik sendromu olanlar ve olmayanlar olarak iki gruba ayrıldı. Tüm hastaların yaşı, cinsiyeti, kilosu, boyu, postoperatif yoğun bakım yatış süreleri, total hastane yatış süreleri ve post-operatif komplikasyonlar (düşük debi send. İnotropi-IABP ihtiyacı, insüline bağımlı diabetes mellitus, aritmi, böbrek yetmezliği, solunum yetmezliği) kayıt altına alınmıştır. Histopatolojik değerlendirmede incelenen mediastinal yağ doku örneklerinde adiposit ve lenfosit nükleusunda Nesfatin-1, Galectin-3, Grehelin and Leptin ekspresyonu yoğunluğu değerlendirilmiştir.
Amaç:
Bu çalışmanın amacı, on-pump koroner arter bypass grefti (CABG) ameliyatı yapılan metabolik sendromu olan ve olmayan hastalarda mediastinal yağ dokusunda Nesfatin-1, Galectin-3, Ghrelin ve Leptin ekspresyonlarını ve postoperatif komplikasyonlarla ilişkisini araştırmaktır.
Anahtar Kelimeler: Açık kalp cerrahisi, Galektin-3, Ghrelin, Leptin, metabolik sendrom, Nesfatin-1, yağ dokusu
Kaynakça
Direk F, Çelik SS. Postoperative problems experienced by patients undergoing coronary artery bypass graft surgery and their self-care ability after discharge. Turkish Journal of Thoracic and Cardiovascular Surgery 2012;20(3):530-535.
Echahidi N, Pibarot P, Després J-P, Daigle J-M, Mohty D, Voisine P, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007;50(9):843-851.
Echahidi N, Mohty D, Pibarot P, Despres J-P, O’Hara G, Champagne J, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(Suppl 11):I213-2199.
Bagheri J, Rezakhanloo F, Valeshabad AK, Bagheri A. Effects of body mass index on the early surgical outcomes after coronary artery bypass grafting. Turkish Journal of Thoracic and Cardiovascular Surgery 2014;22(2):253-259.
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep 2018;20(2):12.
Shimizu H, Ohsaki A, Oh-I S, Okada S, Mori M. A new anorexigenic protein, nesfatin-1. Peptides 2009;30(5):995-998.
Wang XQ, Zheng Y, Fang PF, Song XB. Nesfatin-1 is a potential diagnostic biomarker for gastric cancer. Oncol Lett 2020;19(2):1577-1583.
Khalili S, Shekari Khaniani M, Afkhami F, Mansoori Derakhshan S. NUCB2/Nesfatin-1: A Potent Meal Regulatory Hormone and its Role in Diabetes. Egyptian Journal of Medical Human Genetics 2017;18:105-109.
Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8(1):21-34.
Lok DJA, Van Der Meer P, De La Porte PWBA, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99(5):323-328.
Sancakli Usta C, Turan G, Bulbul CB, Usta A, Adali E. Differential expression of Oct-4, CD44, and E-cadherin in eutopic and ectopic endometrium in ovarian endometriomas and their correlations with clinicopathological variables. Reprod Biol Endocrinol 2020;18(1):116.
Khatib MN, Shankar A, Kirubakaran R, Agho K, Simkhada P, Gaidhane S, et al. Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PLoS One 2015;10(5):e0126697.
Zoladz JA, Konturek SJ, Duda K, Majerczak J, Sliwowski Z, Grandys M, et al. Effect of moderate incremental exercise, performed in fed and fasted state on cardio-respiratory variables and leptin and ghrelin concentrations in young healthy men. J Physiol Pharmacol 2005;56(1):63-85.
Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004;429(6987):72-75.
Yin QS, Shi B, Dong L, Bi L. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 2014;11(1):79-82.
Ravussin A, Youm YH, Sander J, Ryu S, Nguyen K, Varela L, et al. Loss of Nucleobindin-2 Causes Insulin Resistance in Obesity without Impacting Satiety or Adiposity. Cell Rep 2018;24(5):1085-1092.e6.
Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709-712.
Yang Y, Zhang B, Nakata M, Nakae J, Mori M, Yada T. Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells. J Physiol Sci 2019;69(5):733-739.
Kuyumcu MS, Kuyumcu A, Yayla Ç, Özbay MB, Alagöz M, Ünal S, et al. Nesfatin-1 levels in patients with slow coronary flow. Kardiol Pol 2018;76(2):401-405.
Tasatargil A, Kuscu N, Dalaklioglu S, Adiguzel D, Celik-Ozenci C, Ozdem S, et al. Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: Role of the Akt/GSK-3β pathway. Peptides 2017;95:1-9.
Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150(1):232-238.
Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009;381(4):643-638.
Tekin T, Cicek B, Konyaligil N. Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian J Med 2019;51(3):280-284.
Schalla MA, Stengel A. Current Understanding of the Role of Nesfatin-1. J Endocr Soc 2018;2(10):1188-1206.
Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez F, Milani RV, et al. Update on Obesity and Obesity Paradox in Heart Failure. Prog Cardiovasc Dis 2016;58(4):393-400.
Orzano AJ, Scott JG. Diagnosis and treatment of obesity in adults: an applied evidence-based review. J Am Board Fam Pract 2004;17(5):359-369.
